Key points are not available for this paper at this time.
The risk of idiopathic VTE is about three times higher among current users of replacement oestrogens than among non-users. However, the absolute risk is low for both groups and accounts for only a modest increase in morbidity.
Jick et al. (Tue,) studied this question.